Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the 2022 Jefferies Global Healthcare Conference from June 8-10, 2022. Raj Mehra, Ph.D., CEO, and Michael Golembiewski, CFO, will present on June 10 at 12:00 PM ET and engage in one-on-one meetings. This conference will host over 500 healthcare companies and 3,000 investors to discuss investment opportunities and trends in the healthcare sector. For additional details regarding the presentation, registration can be accessed here.

NEW YORK, May 12, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022.

Raj Mehra, Ph.D., Chairman and CEO and Michael Golembiewski, CFO, will present on Friday, June 10th  at 12:00 PM ET and host 1x1 meetings.

The 2022 Jefferies Global Healthcare Conference is an annual gathering where over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs will address near-term and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.

Presentation webcast registration may be accessed here.

For questions about the conference, please email healthcareconference@jefferies.com.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-2022-jefferies-global-healthcare-conference-301545553.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is Seelos Therapeutics participating in on June 10, 2022?

Seelos Therapeutics will present at the 2022 Jefferies Global Healthcare Conference on June 10, 2022.

Who will represent Seelos Therapeutics at the Jefferies Conference?

Raj Mehra, Ph.D., CEO, and Michael Golembiewski, CFO, will represent Seelos Therapeutics.

What is the focus of the 2022 Jefferies Global Healthcare Conference?

The conference focuses on discussing investment opportunities and trends in the healthcare sector.

What time is Seelos Therapeutics' presentation at the Jefferies Conference?

Seelos Therapeutics' presentation is scheduled for June 10, 2022, at 12:00 PM ET.

How can I register for Seelos Therapeutics' presentation at the conference?

Registration for the presentation can be accessed through the conference's official link.